Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Fusion Antibodies Plc ( (GB:FAB) ) has shared an update.
Fusion Antibodies plc reported a decrease in unaudited revenues for the first half of the financial year 2026 compared to the previous year, but an increase from the second half of 2025, with improved gross margins reflecting operational efficiency. The company achieved a significant milestone with a US patent for its OptiMAL® library design and continued its collaboration with the National Cancer Institute, which plans to use the platform for future projects. Fusion secured new contracts, including a stable cell line development for a US biotechnology company and multiple humanization projects, strengthening its industry position. The company anticipates a stronger performance in the second half of the year, supported by a robust order book and promising sales opportunities, and is on track with strategic goals, including the launch of OptiMAL® in December.
The most recent analyst rating on (GB:FAB) stock is a Hold with a £16.50 price target. To see the full list of analyst forecasts on Fusion Antibodies Plc stock, see the GB:FAB Stock Forecast page.
Spark’s Take on GB:FAB Stock
According to Spark, TipRanks’ AI Analyst, GB:FAB is a Neutral.
Fusion Antibodies Plc’s overall stock score is primarily impacted by its weak financial performance, characterized by significant losses and cash flow issues. While technical indicators suggest a positive trend, the negative valuation metrics further weigh down the score. The absence of earnings call data and corporate events leaves the financial and technical aspects as the primary influences.
To see Spark’s full report on GB:FAB stock, click here.
More about Fusion Antibodies Plc
Fusion Antibodies plc is a Belfast-based contract research organization specializing in antibody engineering services for therapeutic drug and diagnostic applications. Established in 2001 as a spin-out from Queen’s University Belfast, the company provides services in antibody generation, development, production, characterization, and optimization. Fusion Antibodies has a broad international client base, including eight of the top 10 global pharmaceutical companies, and aims to accelerate drug development through innovative platforms and cutting-edge science.
Average Trading Volume: 1,673,698
Technical Sentiment Signal: Buy
Current Market Cap: £15.63M
For detailed information about FAB stock, go to TipRanks’ Stock Analysis page.